Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Valneva SE's share price for the quarter that ended in Dec. 2023 was $10.369. Valneva SE's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 69.4 Mil. Therefore, Valneva SE's market cap for the quarter that ended in Dec. 2023 was $719.5 Mil.
Valneva SE's quarterly market cap
declined
from Jun. 2023 ($1,023.4 Mil) to Sep. 2023 ($803.6 Mil) and
declined
from Sep. 2023 ($803.6 Mil) to Dec. 2023 ($719.5 Mil).
Valneva SE's annual market cap
declined
from Dec. 2021 ($2,916.1 Mil) to Dec. 2022 ($880.0 Mil) and
declined
from Dec. 2022 ($880.0 Mil) to Dec. 2023 ($719.5 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Valneva SE's Enterprise Value for Today is $605.4 Mil.
Valneva SE Market Cap Historical Data
The historical data trend for Valneva SE's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Valneva SE's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valneva SE's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valneva SE's Market Cap distribution charts can be found below:
* The bar in red indicates where Valneva SE's Market Cap falls into.
Valneva SE Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Valneva SE's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valneva SE (NAS:VALN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Valneva SE Market Cap Related Terms
Thank you for viewing the detailed overview of Valneva SE's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VALN has been successfully added to your 